Clinical Trials Directory

Trials / Completed

CompletedNCT03439917

Effects of Carnitine Supplementation on Liver and Muscle

Effect of Carnitine Supplementation on Liver Steatosis, Insulin Sensitivity, Plasma Glucose Homeostasis, Skeletal Muscle Metabolism and Energetics: a Pilot Study

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
30 (actual)
Sponsor
University of Nottingham · Academic / Other
Sex
Male
Age
18 Years – 50 Years
Healthy volunteers
Not accepted

Summary

It will be evaluated whether carnitine, a dietary supplement, reduces liver fat and improves metabolism in individuals who have a high concentration of fat within their liver. Participants will be given either Carnitine or placebo, together with a meal replacement milkshake twice daily for 6 months.

Detailed description

NAFLD occurs when too much fat accumulates in liver tissue. This can, over time, cause inflammation and scarring of the liver, eventually leading to chronic liver disease and cirrhosis. It is strongly associated with diabetes and obesity, both of which are endemic in Western societies. Carnitine enables cells in the body to use fat as a fuel, and recent studies have suggested that carnitine supplementation may reduce liver triglyceride content. Muscle and liver are the major sites in the body which coordinate glucose and fat metabolism. As well as assessing the effect of carnitine supplementation on liver fat, its effect on metabolic processes within these tissues will also be measured

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTL-Carnitine tartrate2g L-Carnitine tartrate as a powder consumed twice a day
DIETARY_SUPPLEMENTMeal Replacement Drink325ml dairy-based meal replacement drink ('Slimfast' trademark of KSF Acquisition UK Ltd) consumed twice a day
DIETARY_SUPPLEMENTMaltodextrin2g Maltodextrin powder packaged to mimic carnitine powder consumed twice a day

Timeline

Start date
2018-04-02
Primary completion
2020-08-30
Completion
2021-11-01
First posted
2018-02-20
Last updated
2021-11-30

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT03439917. Inclusion in this directory is not an endorsement.